The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer
Open accessAbstract
Prostate specific membrane antigen (PSMA) is a validated molecular marker for prostate cancer. A series of glutamate-urea (Glu-urea-X) heterodimeric inhibitors of PSMA were designed and synthesized where X = epsilon-N-(o-I, m-I, p-I, p-Br, o-Cl, m-Cl, p-Cl, p-F, H)-benzyl-Lys and epsilon-(p-I, p-Br, p-Cl, p-F, H)-phenylureido-Lys. The affinities for PSMA were determined by screening in a competitive binding assay. PSMA binding of the benzyllysine series was significantly affected by the nature of the halogen substituent (IC(50) values, Cl < I = Br << F = H) and the ring position of the halogen atom (IC(50) values, p-I < o-I << m-I). The halogen atom had little affect on the binding affinity in the para substituted phenylureido-Lys series. Two lead iodine compounds were radiolabeled with (123)I and (131)I and demonstrated specific PSMA binding on human prostate cancer cells, warranting evaluation as radioligands for the detection, staging, and monitoring of prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Chang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 825
Maloney, D. G., Grillo-López, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 636
Ross, J. S., Sheehan, C. E., Fisher, H. A. �., Kaufman, R. P., Kaur, P., Gray, K., Webb, I. J., Gray, G. S., Mosher, R. E., & Kallakury, B. (2003) · PubMed · Cited by 513
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Pinto, J. T., Suffoletto, B. P., Berzin, T. M., Qiao, C. H., Lin, S., Tong, W. P., May, F., Mukherjee, B., & Heston, W. D. W. (1996) · PubMed · Cited by 389
Imaging prostate cancer with 11C-choline PET/CT.
Reske, S. N., Blumstein, N. M., Neumaier, B., Gottfried, H., Finsterbusch, F., Kocot, D., Möller, P., Glatting, G., & Perner, S. (2006) · PubMed · Cited by 250
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
Schülke, N., Varlamova, O. A., Donovan, G. P., Ma, D., Gardner, J. P., Morrissey, D. M., Arrigale, R. R., Zhan, C., Chodera, A. J., Surowitz, K. G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1735443100 · Cited by 232
Smith-Jones, P. M., Vallabahajosula, S., Goldsmith, S. J., Navarro, V., Hunter, C. J., Bastidas, D., & Bander, N. H. (2000) · PubMed · Cited by 212
Smith-Jones, P. M., Vallabhajosula, S., Navarro, V., Bastidas, D., Goldsmith, S. J., & Bander, N. H. (2003) · PubMed · Cited by 184
Murphy, G. P., Elgamal, A. A., Su, S. L., et al. (1998) · PubMed · Cited by 168
Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer
Scher, B., Seitz, M., Albinger, W., Tiling, R., Scherr, M., Becker, H.-C., Souvatzogluou, M., Gildehaus, F.-J., Wester, H.-J., & Dresel, S. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0190-7 · Cited by 158
Murphy, G. P., Elgamal, A. A., Su, S. L., Bostwick, D. G., & Holmes, E. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11<2259::aid-cncr5>3.0.co;2-t · Cited by 150
Pomper, M. G., Musachio, J. L., Zhang, J., Scheffel, U., Zhou, Y., Hilton, J., Maini, A., Dannals, R. F., Wong, D. F., & Kozikowski, A. P. (2002) · Molecular Imaging · doi:10.1162/153535002320162750 · Cited by 138
Self-citationProstate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells
Lapidus, R. G., Tiffany, C. W., Isaacs, J. T., & Slusher, B. S. (2000) · The Prostate · doi:10.1002/1097-0045(20001201)45:4<350::aid-pros10>3.0.co;2-u · Cited by 131
Bařinka, C., Rinnová, M., Šácha, P., Rojas, C. J., Majer, P., Slusher, B. S., & Konvalinka, J. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00715.x · Cited by 123
A Unique Folate Hydrolase, Prostate-Specific Membrane Antigen (PSMA): A Target For Immunotherapy?
Tasch, J. E., Gong, M., Sadelain, M., & Heston, W. D. W. (2001) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v21.i1-3.160 · Cited by 92
Structural Insight into the Pharmacophore Pocket of Human Glutamate Carboxypeptidase II
Bařinka, C., Rovenská, M., Mlčochová, P., Hlouchová, K., Plechanovová, A., Majer, P., Tsukamoto, T., Slusher, B. S., Konvalinka, J., & Lubkowski, J. T. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070133w · Cited by 87
Targeted treatment of prostate cancer
Wang, X., Yin, L., Rao, P., Stein, R. J., Harsch, K. M., Lee, Z., & Heston, W. D. W. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21491 · Cited by 65
Friedrich, S. W., Linz, S. C., Stoll, B. R., Baxter, L. T., Munn, L. L., & Jain, R. K. (2002) · Neoplasia · doi:10.1038/sj.neo.7900260 · Cited by 59
Site-Directed Mutagenesis of Predicted Active Site Residues in Glutamate Carboxypeptidase II
Speno, H., Luthi‐Carter, R., Macias‐Konstantopoulos, W., Valentine, S. L., Joshi, A. R. T., & Coyle, J. T. (1999) · Molecular Pharmacology · doi:10.1124/mol.55.1.179 · Cited by 57
Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II
Stoermer, D., Liu, Q., Hall, M. R., Flanary, J. M., Thomas, A. G., Rojas, C. J., Slusher, B. S., & Tsukamoto, T. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00407-4 · Cited by 46
A simple method for the preparation of 123I and 125I labeled iodobenzodiazepines
McBride, B. J., Baldwin, R. M., Kerr, J. M., & Wu, J.-L. (1991) · International Journal of Radiation Applications and Instrumentation Part A Applied Radiation and Isotopes · doi:10.1016/0883-2889(91)90069-d · Cited by 29
Absorbed Dose Ratios for Repeated Therapy of Neuroblastoma with I-131 mIBG
Flux, G., Guy, M. J., Papavasileiou, P., South, C., Chittenden, S. J., Flower, M. A., & Meller, S. T. (2003) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497803321269359 · Cited by 24
Cited by
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Current use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 611
Targeted therapy using nanotechnology: focus on cancer
Sechi, M., Sanna, V., & Pala, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s36654 · Cited by 493
Szabo, Z., Mena, E., Rowe, S. P., Plyku, D., Nidal, R., Eisenberger, M. A., Antonarakis, E. S., Fan, H., Dannals, R. F., Chen, Y., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0850-8 · Cited by 443
Metadata
- Authors
- Maresca, K. P., Hillier, S. M., Femia, F. J., Keith, D., Barone, C., Joyal, J. L., Zimmerman, C. N., Kozikowski, A. P., Barrett, J. A., Eckelman, W. C., & Babich, J. W.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-12-29
- Volume
- 52
- Issue
- 2
- Pages
- 347-357
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2038578630
- Cited by
- 295
- References
- 23
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.